NCT04154943 - Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 10, 2020

Primary Completion Date

December 1, 2021

Study Completion Date

November 28, 2025

Conditions

Cutaneous Squamous Cell Carcinoma

Interventions

DRUG

Cemiplimab

Intravenous (IV) infusion every 3 weeks (Q3W)

Trial Locations (22)

2065

Regeneron Study Site, St Leonards

3000

Regeneron Study Site, Melbourne

4029

Regeneron Study Site, Herston

10065

Regeneron Study Site, New York

20037

Regeneron Study Site, Washington D.C.

21231

Regeneron Study Site, Baltimore

24105

Regeneron Study Site, Kiel

27710

Regeneron Study Site, Durham

28204

Regeneron Study Site, Charlotte

33176

Regeneron Study Site, Miami

33612

Regeneron Study Site, Tampa

44195

Regeneron Study Site, Cleveland

45147

Regeneron Study Site, Essen

48109

Regeneron Study Site, Ann Arbor

68114

Regeneron Study Site, Omaha

72076

Regeneron Study Site, Tübingen

75390

Regeneron Study Site, Dallas

77030

Regeneron Study Site, Houston

94304

Regeneron Study Site, Palo Alto

02114

Regeneron Study Site, Boston

02215

Regeneron Study Site, Boston

01307

Regeneron Study Site, Dresden